NeuroSense Therapeutics Announces Encouraging Interim Results of Clinical Study in ALS

RAYUS Radiology Quality Institute Distinguished Nationally by Centers for Medicare & Medicaid

Quality Institute Again Earns Certification as Provider-Led Entity for Advanced Diagnostic Imaging Guidance to Clinicians.

LX1550 Multiparameter Remote Monitoring Platform Receives FDA 510 (k) Approval: Reports LifeSignals

Further validation of ability to deliver continuous remote patient vital signs monitoring within both hospital and home settings.

U.S. News & World Report Names Tampa General Hospital as Best in Tampa Bay

This is the sixth consecutive year that Tampa General has been named by U.S. News & World Report as Tampa Bay's top hospital.

September 9, 2020

NeuroSense Therapeutics, a Biotech company developing PrimeC, a combination drug which aims to slow ALS progression, announced today that PrimeC was safe and well-tolerated in the interim analysis of study NST002, a Phase IIa study conducted by Principal Investigator Prof. Vivian Drory in Israel at Tel-Aviv Sourasky Medical Center (TASMC).

Trends toward slowing of disease progression were seen both in ALSFRS-R and Vital Capacity. These trends were noted in the last 3 months of the 6-month study.

NeuroSense Therapeutics notes the study, containing 15 patients, is scheduled to continue for an additional 6 months.

Alon Ben-Noon, CEO of NeuroSense Therapeutics, added: “We are very encouraged by the interim results and are now preparing for more analyses that may reveal additional layers of observations. We intend to initiate an additional clinical trial by the beginning of 2021 with the new PrimeC advanced formulation.”  Jeremy Shefner, MD, PhD, Chair of Neurology at the Barrow Neurological Institute and advisor to the NeuroSense program, said: “These clinical signals, in conjunction with the very promising preclinical results in multiple ALS models, clearly warrant further investigation in a larger, placebo-controlled study.”

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.